Navigation Links
Amgen Statement on European Investor Visit
Date:11/14/2011

THOUSAND OAKS, Calif., Nov. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today issued the following statement:

Amgen will be meeting with investors in Europe this week with a view to raise $1-1.5 billion in Euro and Sterling denominated debt to support its share repurchase program, as well as for general corporate purposes.  The timing of this potential offering will be subject to market conditions.

The debt will not be or have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  Accordingly, the debt, if offered, will be offered only to persons other than "U.S. persons" in compliance with Regulation S under the Securities Act.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2010, and in our periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. 

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.  Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)  

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
2. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
3. Amgen Announces Webcast of 2011 Third Quarter Financial Results
4. Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Conference
7. Amgen to Present at the Baird Healthcare Conference
8. Amgen to Present at the Stifel Nicolaus Healthcare Conference
9. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
10. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
11. Amgen Announces Webcast of 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... --  Responding to Heath Ledger,s father,s recent call ... Chris Cornell in May, the mental health watchdog ... online psychiatric drug side effects search engine ... drug risks. The father of the late ... overdose, has called for tighter rules on prescription drugs. Speaking ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 2017 , ... All-Star Insurance, a family managed agency that offers insurance management ... announcing the launch of a new charity drive to benefit women in the area ... reveal that an estimated 252, 710 new cases of invasive or high risk breast ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the Houston area with access to asset protection and financial planning services, is ... aimed at improving the lives of children with cancer and other chronic diseases. ...
(Date:6/22/2017)... ... , ... Plastic Surgery Associates is proud to report that founding surgeon, Francisco ... and information firm, Castle Connolly, releases their list of the most notable and trusted ... time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... , ... Groove Ring is excited to announce they've partnered with Olympic runner ... and all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the ... From the rock face to the auto shop, Groove Ring is the world's first ...
(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
Breaking Medicine News(10 mins):